Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25384121 | 1.00 | MMP13 (0.30) | MMP13AAK1HDAC6 | |
| SCHEMBL25186344 | 0.86 | AAK1 (0.31) | MMP13AAK1HDAC6 | |
| SCHEMBL31407614 | 0.86 | AAK1 (0.31) | MMP13AAK1HDAC6 | |
| SCHEMBL25186343 | 0.86 | AAK1 (0.31) | MMP13AAK1HDAC6 | |
| SCHEMBL2160514 | 0.84 | CA1 (0.33) | MMP13AAK1HDAC6 | |
| SCHEMBL67120 | 0.84 | CA1 (0.33) | MMP13AAK1HDAC6 | |
| SCHEMBL59435 | 0.84 | CA1 (0.33) | MMP13AAK1HDAC6 | |
| SCHEMBL25385348 | 0.83 | CA12 (0.36) | AAK1 | |
| SCHEMBL31287322 | 0.83 | MMP13 (0.30) | MMP13AAK1HDAC6 | |
| SCHEMBL6843570 | 0.82 | AAK1 (0.32) | MMP13AAK1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
| CN-108794422-B | Heterocyclic compounds as PD-L1 inhibitors | 南京圣和药业股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | MMP13 2905/4885AAK1 4583/4885HDAC6 1713/4885 |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | MMP13 645/4885AAK1 1976/4885HDAC6 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.